Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath
Executive Summary
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
You may also be interested in...
Curious Case Of LHQW: Behind The TCM Central To China’s COVID Zero Policies
The role of a traditional Chinese medicine provided to the general public in China to fend off COVID-19 is controversial given limited evidence and even misleading, some say.
China Bioventures' Role In Virus Fight Helps Secure $721m In New Funding, Deals
Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.